Michael Nicolas
Psychiatric/Mental Health · Orange, CANPI 1497284202
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,545 and has fallen 99.0% since, to $26 in 2025. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$765
- AbbVie$616
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$505
- Johnson & Johnson$473
- Alkermes, Inc.$380
- Otsuka America Pharmaceutical, Inc.$335
- plus $2K from 12 others
What the payments were for
- Food & beverage$4,84299%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 44 | $765 |
| AbbVie | 41 | $616 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $505 |
| Johnson & Johnson | 19 | $473 |
| Alkermes, Inc. | 11 | $380 |
| Otsuka America Pharmaceutical, Inc. | 12 | $335 |
| Vanda Pharmaceuticals Inc. | 28 | $323 |
| Neurocrine Biosciences, Inc. | 14 | $300 |
| Indivior Inc. | 10 | $257 |
| Novo Nordisk | 6 | $222 |
| Sunovion Pharmaceuticals Inc. | 14 | $202 |
| Lundbeck LLC | 9 | $181 |
| Biogen | 1 | $96 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Ironshore Pharmaceuticals Inc. | 3 | $59 |
| Noven Therapeutics, LLC | 2 | $39 |
| Eisai Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$500
- ABILIFY MAINTENA$121
- Wegovy$121
How this compares
$4,892 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 18 | $2,921 |
| Risperidone | 18 | $295 |
| Olanzapine | 12 | $185 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Orange
- Yvette ElpidioOrange$43K
- Michael ChoiOrange$19K
- Rachel AlbaughOrange$12K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.